TYRA (Tyra Biosciences) Other Net Income (Loss) : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences Other Net Income (Loss)?

Tyra Biosciences's Other Net Income (Loss) for the three months ended in Sep. 2024 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Tyra Biosciences Other Net Income (Loss) Historical Data

The historical data trend for Tyra Biosciences's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences Other Net Income (Loss) Chart

Tyra Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Tyra Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial														-	-	-	-	-

Tyra Biosciences Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Tyra Biosciences Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyra Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2656 State Street, Carlsbad, CA, USA, 92008

Website

https://www.tyra.bio

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Executives

Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alan Fuhrman	officer: Chief Financial Officer	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Todd Harris	director, officer: Chief Executive Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Daniel Bensen	officer: Chief Operating Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ali D. Fawaz	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alta Partners Nextgen Fund Ii, L.p.	10 percent owner	4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert J More	director, 10 percent owner	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Melissa Mccracken	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008